Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Clinical Trials
19
12 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2016
Active, not recruiting
8
42.1%
Completed
1
5.3%
Enrolling By Invitation
1
5.3%
Not yet recruiting
3
15.8%
Recruiting
5
26.3%
Withdrawn
1
5.3%
No approval data available
- Vera Therapeutics reported that Trutakna met all prespecified endpoints in the final ORIGIN 3 analysis of 428 adults with primary IgA nephropathy at risk of progression. - Annualized eGFR slope through 104 weeks was -0.6 mL/min/1.73m2/year with Trutakna versus -5.6 with placebo, a 5.0 mL/min/1.73m2/year treatment effect (p<0.0001). - Composite kidney disease progression events occurred in 11 Trutakna patients versus 38 on placebo, a 76% risk reduction (hazard ratio 0.24; 95% CI 0.12, 0.48). - Vera plans to submit a supplemental BLA in Q4 2026 for full approval, with more than 350 patient start forms generated in the first ten weeks of launch.
- The FDA approved the first therapy for primary IgA nephropathy in December 2021, and since then multiple novel drugs have received accelerated approval, transforming the treatment landscape. - A 2016 Kidney Health Initiative partnership redefined surrogate endpoints, establishing proteinuria reduction at 9 months as an acceptable marker, which made clinical trials feasible and affordable. - Currently, five therapies are approved in the U.S., including sparsentan, atrasentan, budesonide, sibeprenlimab, and iptacopan, with additional agents like atacicept and povetacicept under FDA review. - Experts emphasize that despite the "embarrassment of riches" in therapies, early patient identification remains the biggest challenge, as many patients present too late for optimal intervention.
- The FDA faces a packed July 2026 with PDUFA dates for therapies targeting hepatocellular carcinoma, multiple myeloma, IgA nephropathy, and advanced breast cancer. - Elevar Therapeutics' rivoceranib plus camrelizumab could become a new first-line option for unresectable hepatocellular carcinoma based on phase 3 CARES-310 trial data. - Vera Therapeutics seeks accelerated approval for atacicept in IgA nephropathy after the ORIGIN phase 3 trial met its primary endpoint of reduced proteinuria at week 36. - MannKind's FUROSCIX ReadyFlow Autoinjector, delivering subcutaneous furosemide in under 10 seconds, faces a July 26 decision for edema in chronic heart failure and CKD.
- Eight biotech companies raised a record $3.5 billion in a single night following the American Society of Hematology conference, marking the busiest day ever in biotech fundraising. - Terns Pharmaceutical led the surge with a $650 million offering after presenting Phase I leukemia trial data showing 64% response rates, with potential peak sales projected at $2.5 billion. - Fulcrum Therapeutics raised $175 million following positive Phase Ib results for its sickle cell disease treatment in expectant mothers, demonstrating meaningful increases in fetal hemoglobin levels. - The fundraising wave reflects strong biotech sector performance with the NYSE Arca Biotechnology Index up 27% year-to-date, driven by positive trial results and increased M&A activity.
- Vera Therapeutics successfully completed a $300 million public offering of Class A common stock, selling 7,058,824 shares at $42.50 per share. - The biotechnology company focuses on developing treatments for serious immunologic diseases, with lead candidate atacicept targeting autoimmune conditions. - Atacicept is a fusion protein that blocks BAFF and APRIL pathways, designed to reduce autoantibody production in diseases like IgA nephropathy and lupus nephritis. - The company's pipeline also includes VT-109, a next-generation BAFF/APRIL targeting fusion protein, and MAU868 for BK virus neutralization in kidney transplant recipients.
- Vera Therapeutics has announced positive Phase 3 data for its treatment of IgA nephropathy (IgAN), a significant milestone for the company's clinical development program. - The positive results have prompted analysts and investors to reassess the company's valuation following the successful trial outcomes. - The Phase 3 data represents a major advancement in addressing IgAN, a progressive kidney disease with limited treatment options.
- Atacicept demonstrated a 45.7% reduction in proteinuria and 41.8-point placebo-adjusted advantage in the phase 3 ORIGIN 3 trial for IgA nephropathy, marking significant progress in targeted B-cell modulation therapy. - Finerenone achieved a 25% relative reduction in urinary albumin-to-creatinine ratio in type 1 diabetes patients with chronic kidney disease, representing the first new therapeutic option for this population in nearly 30 years. - Fish oil supplementation reduced serious cardiovascular events by 43% in maintenance hemodialysis patients, offering a simple intervention with substantial clinical impact for this high-risk population. - Multiple novel therapies including MIL62, povetacicept, and telitacicept showed promising results in glomerular diseases, highlighting the field's shift toward precision medicine and disease-modifying treatments.
- Vera Therapeutics reported positive results from its Phase 3 ORIGIN trial evaluating a treatment for IgA nephropathy (IgAN), a progressive kidney disease. - The company has submitted data to the FDA following the successful Phase 3 trial outcomes, marking a significant regulatory milestone. - Despite the positive clinical developments, Vera Therapeutics stock experienced volatility with both gains and subsequent declines following the announcement. - The ORIGIN trial represents a potential breakthrough in addressing IgA nephropathy, which currently has limited treatment options for patients.
- DelveInsight's 2025 pipeline report reveals over 35 companies are actively developing more than 40 investigational therapies for lupus nephritis treatment. - Hoffmann-La Roche leads with obinutuzumab in Phase III trials, while other promising candidates include ADX-097 from Q32 Bio and NKX019 from Nkarta Therapeutics. - The FDA granted Fast Track designation to AlloNK from Artiva Biotherapeutics in February 2024 for combination therapy with rituximab or obinutuzumab. - Lupus nephritis affects patients with systemic lupus erythematosus and can progress to chronic kidney disease or end-stage renal disease without effective treatment.
- Otsuka Pharmaceutical is advancing efforts to challenge Vera Therapeutics in developing effective treatments for kidney diseases, with both companies focusing on innovative approaches to address unmet medical needs. - New data has emerged linking GLP-1 receptor agonists to potential eye-related complications, prompting increased scrutiny from regulatory bodies and healthcare professionals. - The safety concerns involve GLP-1 drugs widely prescribed for managing Type 2 diabetes and obesity, with reports suggesting a potential association with retinal issues.
